Since PCSK9 inhibitors have been shown to effectively reduce the risk of ASCVD and tendon xanthoma (Bea et al., 2017), the underlying mechanism and exact effects are waiting to be revealed. The gene discussed is PCSK9; the disease is atherosclerosis.